

MARKET ANNOUNCEMENT

COMPLETION OF SHARE PURCHASE PLAN – TOTAL CAPITAL RAISING WITH PRIVATE PLACEMENT OF \$2,144,500

Sydney, Australia: Friday 21 August 2015: Uscom (ASX code: UCM) (the **Company** or **Uscom**), a revenue stage, cardiovascular medical technology company and manufacturer of the USCOM 1A, is pleased to advise that its Share Purchase Plan (**SPP**) closed on 14 August 2015.

Applications from shareholders were received for a total of \$194,500 under the SPP. Underwriter Patersons Securities Limited has been notified of the resulting shortfall and has elected to top up its position by way of a placement of additional shares for a total amount of \$400,000.05.

Together with the capital raising by private placement of \$1.55 million announced by the Company on 20 July 2015, this results in a total capital raising by the Company of \$2,144,500 before expenses.

Uscom thanks all shareholders who participated in the SPP for their support.

About Uscom

Uscom Limited (UCM) is an ASX listed cardiovascular medical device company. Uscom is an innovative developer and manufacturer of premium cardiovascular devices and has two practice leading technologies in the field of cardiovascular monitoring, the USCOM 1A and the Uscom BP+. Both devices are clinically validated with FDA, CE and TGA regulatory registration, and are currently being marketed into global distribution networks.

The USCOM 1A is a simple, cost-effective and non-invasive device that measures heart function, detects circulatory abnormalities and guides treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, heart failure, and for the guidance of fluid therapy.

The Uscom BP+ is a supra systolic Central Blood Pressure monitor and replaces older and more widespread sub systolic Blood Pressure monitoring technology. Central Blood Pressure is emerging as the new standard of care in hypertension and heart failure. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and arterial pulse pressure waveforms, measures otherwise only available by cardiac catheterisation. The Uscom BP+ is simple to use and measures from a familiar upper arm cuff, and requires no complex training, and has applications in cardiology, intensive care, general practice and home care.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Assoc. Professor Rob Phillips
Executive Chairman
rob@uscom.com.au

Catherine Officer
Company Secretary
secretary@uscom.com.au